SAGA Diagnostics is redefining the early detection of molecular residual disease (MRD), empowering treatment decisions with greater insight and confidence
SAGA Diagnostics is redefining the early detection of molecular residual disease (MRD), empowering treatment decisions with greater insight and confidence. Their flagship product, Pathlight, is an ultra-sensitive, blood-based, multi-cancer MRD test available for commercial use in the U.S. for early-stage breast cancer.